Aprea Therapeutics Inc expected to post a loss of 44  cents a share - Earnings Preview

Aprea Therapeutics

11/03/2022 12:04

* Aprea Therapeutics Inc  APRE.OQ   APRE.O  is expected
to show no
change in quarterly revenue when it reports  results on March 14
(estimated). 
    * ​Refinitiv's mean analyst estimate for Aprea Therapeutics
Inc is
for a loss of 44 cents per share. For the same quarter last
year, the company reported a loss of 73 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $4​, above​ its last closing price of $1.82.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.45       -0.45      -0.45     Met     0.6
 Jun. 30 2021  -0.46       -0.47      -0.48     Missed  -2.7
 Mar. 31 2021  -0.48       -0.49      -0.46     Beat    6.6​
 Dec. 31 2020  -0.67       -0.64      -0.73     Missed  -13.6
 ​​Sep.        -0.76       -0.76      -0.58     Beat    23.7
 30 2020                                                
 Jun. 30 2020  -0.60       -0.60      -0.78     Missed  -29.5​
 Mar. 31 2020  -0.57       -0.57      -0.45     Beat    20.7
 Dec. 31 2019              -0.40      -0.64     Missed  -60
 This summary was machine generated March 11 at 12:04 GMT.  All
figures in US dollars  unless otherwise stated